DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Meg Tirrell"


25 mentions found


☆ Regeneron's Dupixent shows promise as COPD treatment
  + stars: | 2023-03-23 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRegeneron's Dupixent shows promise as COPD treatmentCNBC's Meg Tirrell joins 'Closing Bell' to report that Regeneron's drug Dupixent has shown promise in treating COPD during phase 3 results.
☆ Sen. Bernie Sanders grills Moderna CEO over Covid vaccine prices during hearing
  + stars: | 2023-03-22 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSen. Bernie Sanders grills Moderna CEO over Covid vaccine prices during hearingCNBC's Meg Tirrell reports on the Senate hearing on drug prices, which featured an exchange between Sen. Bernie Sanders and Moderna CEO Stéphane Bancel.
☆ SVB fallout: The impacts on the biotech sector
  + stars: | 2023-03-13 | by ( Meg Tirrell | ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSVB fallout: The impacts on the biotech sectorCNBC's Meg Tirrell reports on how the SVB fallout could impact biotech investors.
☆ New weight loss drugs will help tackle America's obesity epidemic, says Dr. Scott Gottlieb
  + stars: | 2023-03-07 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNew weight loss drugs will help tackle America's obesity epidemic, says Dr. Scott GottliebDr. Scott Gottlieb, former FDA commissioner, and CNBC's Meg Tirrell join 'Power Lunch' to discuss WeightWatchers upcoming telehealth deal, new weight loss drugs coming to market and regulatory considerations associated with long-term medicine use.
☆ WW International CEO on weight loss drugs: Still critical you make the right lifestyle changes
  + stars: | 2023-03-07 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWW International CEO on weight loss drugs: Still critical you make the right lifestyle changesCNBC's Meg Tirrell talks with Sima Sistani, WW International CEO, on 'Closing Bell: Overtime' to discuss the company's stock surge after announcing it had acquired Sequence, a telehealth platform that helps treat obesity.
☆ The quality of your clinical data drives everything, says Reata Pharma CEO Warren Huff
  + stars: | 2023-03-02 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe quality of your clinical data drives everything, says Reata Pharma CEO Warren HuffWarren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder receiving FDA approval.
☆ Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugs
  + stars: | 2023-03-01 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugsCNBC's Meg Tirrell and David Ricks, Eli Lilly CEO, joins 'Closing Bell: Overtime' to discuss the company's decision to slash insulin prices. He also discusses his economic outlook and the timeline for approval of drugs in its pipeline.
☆ Eli Lilly cuts insulin prices by 70%
  + stars: | 2023-03-01 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly cuts insulin prices by 70%CNBC's Meg Tirrell joins 'The Exchange' to discuss Eli Lilly's decision to set insulin price caps, the motivations behind the company's decision, and whether or not other insulin producers will join them in cutting prices.
☆ FDA advisory panel votes in favor of adult RSV vaccine from GSK PLC
  + stars: | 2023-03-01 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisory panel votes in favor of adult RSV vaccine from GSK PLCCNBC's Meg Tirrell joins 'Power Lunch' to discuss GSK PLC's RSV vaccine receiving FDA support, ongoing questions around the drug's approval and the timeline for the drug to be available for children.
☆ As we work more on the human genome project, the market for rare disease therapies grows, says Nord CEO
  + stars: | 2023-02-28 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAs we work more on the human genome project, the market for rare disease therapies grows, says Nord CEOCNBC's Meg Tirrell, Nord CEO Peter Saltonstall and Boston Children's Hospital's Dr. Olaf Bodamer join 'Power Lunch' to discuss pharmaceutical companies developing treatments for rare disease, the growth expectations for rare disease pharmaceuticals and the state of competition in the rare disease treatment space.
☆ FDA advisers support Pfizer's RSV vaccine for older adults
  + stars: | 2023-02-28 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers support Pfizer's RSV vaccine for older adultsCNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on FDA support for a Pfizer RSV vaccine for adults 65 and over.
☆ Novavax stock down on concern over whether the company can continue
  + stars: | 2023-02-28 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovavax stock down on concern over whether the company can continueCNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Novavax's warning that it may not be able to continue as a company. Also, Sarepta shares rise on FDA signaling no advisory meeting on gene therapy.
☆ Moderna and Merck receive FDA breakthrough status for personalized cancer vaccine
  + stars: | 2023-02-23 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna and Merck receive FDA breakthrough status for personalized cancer vaccineCNBC's Meg Tirrell reports on news from Moderna and Merck.
☆ Moderna, Merck receives FDA breakthrough status for personalized cancer vaccine
  + stars: | 2023-02-22 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna, Merck receives FDA breakthrough status for personalized cancer vaccineCNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Merck and Moderna receiving FDA breakthrough status for a personalized cancer vaccine.
☆ Novo Nordisk CEO on safety concerns associated with off-label use of diabetes drugs
  + stars: | 2023-02-06 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk CEO on safety concerns associated with off-label use of diabetes drugsCNBC's Meg Tirrell joins 'Closing Bell' to report on rapid prescription growth for diabetes medicine, celebrities using Ozempic and Wegovy for weight loss and the safety related to broad use of medicines.
☆ Pfizer responds to White House plans to end Covid public health emergency
  + stars: | 2023-01-31 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer responds to White House plans to end Covid public health emergencyCNBC's Meg Tirrell joins 'Halftime Report' for a breaking news update regarding the White House decision to end the Covid health emergency this May.
☆ Appeals court dismisses Johnson and Johnson talc bankruptcy case
  + stars: | 2023-01-30 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAppeals court dismisses Johnson and Johnson talc bankruptcy caseCNBC's Meg Tirrell joins 'Halftime Report' to report on the U.S. appeals court decision to toss out Johnson and Johnson's talc powder settlements in to a bankruptcy case, the reasons behind the ruling, and the next steps for J&J.
☆ Moderna's phase three RSV trial found to be 83.7% effective in older adults
  + stars: | 2023-01-17 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna's phase three RSV trial found to be 83.7% effective in older adultsCNBC's Meg Tirrell joins 'Closing Bell' to discuss Moderna's phase three trial results for its RSV vaccine, the decision to submit the vaccine for regulatory review and the competitive landscape for RSV vaccines.
☆ Regeneron CEO on the prospects for its eye drug Eylea
  + stars: | 2023-01-10 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRegeneron CEO on the prospects for its eye drug EyleaCNBC's Meg Tirrell sits down with Regeneron CEO Len Schleifer to discuss the company's future, next-gen COVID antibody drug, and more.
☆ Novartis generated $40 billion in innovative medicine sales, says CEO
  + stars: | 2023-01-10 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis generated $40 billion in innovative medicine sales, says CEOCNBC's Meg Tirrell sits down with Dr. Vas Narasimhan, CEO of Novartis International on drug development and future of the company.
☆ CMS limiting coverage of Alzheimer's drug not a 'fixed' policy, says FDA's Robert Califf
  + stars: | 2023-01-10 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCMS limiting coverage of Alzheimer's drug not a 'fixed' policy, says FDA's Robert CaliffCNBC's Meg Tirrell and Dr. Robert Califf, FDA commissioner, joins 'Power Lunch' to discuss Biogen's Alzheimer's drug and the health care sector.
☆ Watch CNBC's full interview with Moderna CEO Stephane Bancel
  + stars: | 2023-01-09 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Moderna CEO Stephane BancelCNBC’s Meg Tirrell joins ‘Closing Bell’ to talk with Moderna CEO Stephane Bancel about the company’s Covid vaccine sales in 2022 and his projections for 2023.
☆ Pfizer CEO: 2022 was one of the most successful years in our corporate history
  + stars: | 2023-01-09 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer CEO: 2022 was one of the most successful years in our corporate historyCNBC's Meg Tirrell sits down with Pfizer CEO Albert Bourla to discuss the Covid crisis and Pfizer's future in producing 19 new products in the next 18 months.
☆ We are in discussion with the Chinese government over the Covid vaccine, says Moderna CEO
  + stars: | 2023-01-09 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe are in discussion with the Chinese government over the Covid vaccine, says Moderna CEOCNBC’s Meg Tirrell joins ‘Closing Bell’ to talk with Moderna CEO Stephane Bancel about the company’s Covid vaccine sales in 2022 and his projections for 2023.
☆ FDA approves Biogen's Alzheimer's drug
  + stars: | 2023-01-06 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA approves Biogen's Alzheimer's drugCNBC's Meg Tirrell reports on Biogen and the company receiving FDA approval for an Alzheimer's treatment.
<< prev 2 next >>
Total: 25